BR112019026916A2 - composições de ésteres de ácido canabidiólico e usos das mesmas - Google Patents

composições de ésteres de ácido canabidiólico e usos das mesmas Download PDF

Info

Publication number
BR112019026916A2
BR112019026916A2 BR112019026916-9A BR112019026916A BR112019026916A2 BR 112019026916 A2 BR112019026916 A2 BR 112019026916A2 BR 112019026916 A BR112019026916 A BR 112019026916A BR 112019026916 A2 BR112019026916 A2 BR 112019026916A2
Authority
BR
Brazil
Prior art keywords
branched
linear
cbda
disease
compound according
Prior art date
Application number
BR112019026916-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Raphael Mechoulam
Linda Parker
Roger Pertwee
Aron WELLER
Joseph Tam
Christeen HAJ
Reem Smoum
Original Assignee
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.
University Of Guelph
Bar Ilan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd., University Of Guelph, Bar Ilan University filed Critical Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.
Publication of BR112019026916A2 publication Critical patent/BR112019026916A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/94—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12—Acetic acid esters
    • C07C69/16—Acetic acid esters of dihydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/28—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with dihydroxylic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR112019026916-9A 2017-06-20 2018-06-20 composições de ésteres de ácido canabidiólico e usos das mesmas BR112019026916A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762522243P 2017-06-20 2017-06-20
US62/522,243 2017-06-20
PCT/IL2018/050678 WO2018235079A1 (en) 2017-06-20 2018-06-20 CANNABIDIOLIC ACID ESTER COMPOSITIONS AND USES THEREOF

Publications (1)

Publication Number Publication Date
BR112019026916A2 true BR112019026916A2 (pt) 2020-06-30

Family

ID=62875079

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019026916-9A BR112019026916A2 (pt) 2017-06-20 2018-06-20 composições de ésteres de ácido canabidiólico e usos das mesmas

Country Status (12)

Country Link
US (1) US11440870B2 (cg-RX-API-DMAC7.html)
EP (1) EP3509638B1 (cg-RX-API-DMAC7.html)
JP (1) JP2020524679A (cg-RX-API-DMAC7.html)
CN (2) CN121534035A (cg-RX-API-DMAC7.html)
AU (1) AU2018287018B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019026916A2 (cg-RX-API-DMAC7.html)
CA (1) CA3067512A1 (cg-RX-API-DMAC7.html)
DK (1) DK3509638T3 (cg-RX-API-DMAC7.html)
ES (1) ES2909350T3 (cg-RX-API-DMAC7.html)
MX (1) MX389847B (cg-RX-API-DMAC7.html)
PT (1) PT3509638T (cg-RX-API-DMAC7.html)
WO (1) WO2018235079A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
US11440870B2 (en) 2017-06-20 2022-09-13 University Of Guelph Cannabidiolic acid esters compositions and uses thereof
US11202771B2 (en) 2018-01-31 2021-12-21 Treehouse Biotech, Inc. Hemp powder
EP3864000A4 (en) 2018-10-10 2022-08-10 Treehouse Biosciences, Inc. CANNABIGEROL SYNTHESIS
US20220054380A1 (en) * 2018-12-25 2022-02-24 Epm (Ip), Inc. Cannabidioloic acid esters for cosmetic or edible compositions
CN118831076A (zh) * 2019-03-12 2024-10-25 Epm (Ip)公司 大麻素酸酯组合物及其用途
MX2022002183A (es) 2019-08-22 2022-05-24 Epm Group Inc Composiciones de éster de ácido cannabinoide y sus usos.
WO2021137224A1 (en) * 2020-01-01 2021-07-08 Epm Group, Inc. Cannabidiolic acid esters for treating muscular dystrophy
IL275108A (en) * 2020-06-03 2022-01-01 Epm Ip Inc Abnormal acid cannabidiol (abn-cbd) derivatives and their uses
LT4243797T (lt) * 2020-11-16 2026-06-10 Orcosa Inc. Greitos infuzijos platforma ir kompozicijos, skirtos žmonių terapiniam gydymui
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
US20240041904A1 (en) * 2020-12-24 2024-02-08 Buzzelet Development And Technologies Ltd. Compositions comprising cannabinoid acid esters
CN117813081A (zh) * 2021-07-13 2024-04-02 Epm(Ip)公司 用于治疗普拉德-威利综合征的大麻二醇酸酯
US20230066947A1 (en) * 2021-08-04 2023-03-02 Max Hammond Method for the augmentation of substance abuse therapies using cannabinoid formulations

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2318468A1 (fr) 1975-07-17 1977-02-11 Jaeger Dispositif electronique d'enregistrement et de lecture de donnees concernant differents parametres au cours d'un cycle predetermine, fonction de l'un desdits parametres
US5342971A (en) 1992-12-29 1994-08-30 The Australian National University Process for the preparation of dibenzo[b,d]pyrans
CA2340444A1 (en) 1998-05-04 1999-11-11 The University Of Connecticut Cannabinoids selective for the cb2 receptor
IL136839A (en) 2000-06-16 2006-12-10 Yissum Res Dev Co Pharmaceutical compositions comprising cannabidiol derivatives, and processes for the preparation of same
JP2008502690A (ja) 2004-06-15 2008-01-31 アンドリュー シァン チェン, リン脂質組成物ならびにその調製方法および使用方法
EP2578561A1 (en) * 2005-09-29 2013-04-10 Albany Molecular Research, Inc. Processes for the production of cannabidiol derivatives and intermediates thereof
CN101384012B (zh) * 2008-10-22 2012-05-23 华为终端有限公司 系统端和终端的交互媒体文档更新方法及装置
DE102009019322A1 (de) 2009-04-30 2010-11-11 The Health Concept Gmbh Verfahren zur Herstellung von Synthetischen Cannabinoiden
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2494461A (en) 2011-09-12 2013-03-13 Gw Pharma Ltd Phytocannabinoids for use in the treatment of invasive cancers or metastases
GB2515312A (en) 2013-06-19 2014-12-24 Gw Pharma Ltd The use of phytocannabinoids in the treatment of ovarian carcinoma
ES2547354T3 (es) * 2013-09-03 2015-10-05 Symrise Ag Mezclas de compuestos cannabinoides, su preparación y uso
US9701618B2 (en) * 2014-04-16 2017-07-11 Vivacell Biotechnology España S.L. Cannabidiol quinone derivatives
GB2527590A (en) 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
GB2531283A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiols in the treatment of degenerative skeletal muscle diseases
EP3061450A1 (de) 2015-02-26 2016-08-31 Symrise AG Mischungen cannabinoider Verbindungen, deren Herstellung und Verwendung
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
CN106810426B (zh) 2016-12-29 2020-05-08 暨明医药科技(苏州)有限公司 一种大麻二酚的合成方法
US11440870B2 (en) 2017-06-20 2022-09-13 University Of Guelph Cannabidiolic acid esters compositions and uses thereof
WO2019234728A1 (en) 2018-06-04 2019-12-12 Al&Am Pharmachem Ltd. Cannabinolic acid derivatives and uses thereof

Also Published As

Publication number Publication date
DK3509638T3 (da) 2022-04-11
AU2018287018A1 (en) 2020-01-30
EP3509638A1 (en) 2019-07-17
MX389847B (es) 2025-03-20
ES2909350T3 (es) 2022-05-06
CA3067512A1 (en) 2018-12-27
JP2020524679A (ja) 2020-08-20
CN111032088A (zh) 2020-04-17
US11440870B2 (en) 2022-09-13
WO2018235079A1 (en) 2018-12-27
CN121534035A (zh) 2026-02-17
EP3509638B1 (en) 2022-01-12
PT3509638T (pt) 2022-03-02
AU2018287018B2 (en) 2022-04-28
MX2019015311A (es) 2022-02-02
US20200115317A1 (en) 2020-04-16

Similar Documents

Publication Publication Date Title
ES2909350T3 (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas
Pertwee et al. Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5‐HT1A receptor‐mediated suppression of nausea and anxiety in rats
ES2708808T3 (es) Tetrahidrocannabivarina para uso en el tratamiento de náuseas y vómitos
US8148354B2 (en) Use of 20(S)-protopanaxadiol in manufacture of antidepressants
CN102000072A (zh) 偶联有一氧化氮供体的抗肿瘤天然药物及其医药用途
CN101848711A (zh) 一种药物组合物及其在制备治疗脑血管病药物中的应用
CN106102737A (zh) 色甘酸衍生物以及成像和治疗的相关方法
CA2917815C (en) Organophosphates for treating afflictions of the skin
CN1592616A (zh) 与神经甾体活性降低相关的疾病的治疗中的gaba增强剂
US20210369698A1 (en) Treating Dermatological Conditions with Chloroquine and/or Hydroxychloroquine
CN103948600A (zh) 用于治疗特定癌症的包含rdea119/bay869766的药物组合
WO2005084654A2 (en) Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
JP2018177739A (ja) Trpa1活性化剤
Verma et al. A review of patents on therapeutic potential and delivery of hydroge n sulfide
Class et al. Patent application title: CANNABIDIOLIC ACID ESTERS COMPOSITIONS AND USES THEREOF Inventors: Raphael Mechoulam (Jerusalem, IL) Linda Parker (Campbell River, British Columbia, CA) Roger Pertwee (Aberdeen, Scotland, GB) Aron Weller (Shoham, IL) Joseph Tam (Jerusalem, IL) Christeen Haj (Nazareth Hit, IL) Reem Smoum (Jerusalem, IL)
CN107446010A (zh) 一种红霉素衍生物及其制备方法和应用
JP2005538098A (ja) ヘムオキシゲナーゼレベルの上昇を必要とする治療上の処置におけるレインの使用
HK40028173A (en) Cannabidiolic acid esters compositions and uses thereof
Nakamura et al. Modification of cocaine‐induced behavioral and neurochemical effects by serotonin1A receptor agonist/antagonist in mice
CN106038521A (zh) 一种丹皮酚同系物的抗炎活性及其制剂应用
CN104586835B (zh) 穿心莲内酯的医药用途
US3433875A (en) The improvement of mental performance with potassium n-acetyl dl aminosuccinate
CN110003157A (zh) 一种具有抗焦虑作用的新型黄酮类化合物及其应用
CN112190570B (zh) 天麻来源衍生物在制备治疗急性或慢性疼痛药物中的用途
CN107158020A (zh) 一种眼科用药物组合物及其制备方法

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements